الصفحة 1 من عند 25 النتائج
Glioblastoma (GBM) is the most common primary brain tumor and also has the worst prognosis with a mean survival time below 1 year and a 5-year survival rate of less than 2%.
AF is a 41kilodalton endogenous and essential protein encompassing antisecretory and anti-inflammatory effect. Endogenous AF
Background:
Osteosarcoma (OS) is the most common type of primary malignant bone tumor in children and adolescents. The overall survival rate is dramatically reduced by the development of metastases, often pulmonary. Solid malignant tumors, such as OS, often develop a hypoxic microenvironment, which
A phase II study in relapsing glioblastomas (GBM) using concurrent intraarterial carboplatin chemoradiation therapy.
BACKGROUND - Contemporary treatment of GBM brain tumors involves a first-line treatment in which the patient receives a surgical procedure followed by a combination of radiation and
PRIMARY OBJECTIVES:
I. To estimate the efficacy of HIF-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma.
SECONDARY OBJECTIVES:
I. To estimate the efficacy of PT2385 as
BACKGROUND Radiation Necrosis: Stereotactic radiosurgery has become integral in treatment of brain tumors and arteriovenous malformations (AVM). In up to 10% of cases, this can lead to radiation necrosis (RN) with significant surrounding vasogenic edema and mass effect. Medical treatment for RN
Rationale: Non-invasive imaging of hypoxia with the aid of PET-scans could help to select the patients having a hypoxic tumor, who could be treated with specific anti-hypoxic treatments. The added value of additional anti-hypoxic treatments depends on the presence of hypoxia and adequate patient
Glioma is the most frequent malignant primary brain tumor and remains a lethal disease with a dismal prognosis. Glioblastoma (GBM) accounts approximately 50% of all glioma and among these tumors, are the most malignant. GBM are characterized by a higher cellular density and by the ample existence of
This study is a multi-centre randomized controlled, open label, phase II trial for patients with de-novo GBM.
Eligible patients will be randomized between arm A and arm B:
Arm A (standard): Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30
This trial has been designed as an open label, single center combination phase I trial. The primary objective is to determine the maximum tolerated dose (MTD) for chloroquine (CQ) in combination with concurrent radiotherapy with daily temozolomide in patients with a newly diagnosed GBM.
Eligible
We propose a study to demonstrate quantitative oxygen saturation estimation in GBM is feasible with qBOLD and it correlates with established histopathological markers of hypoxia and angiogenesis, and targeted intraoperative oxygen measurement.
All patients will undergo surgery as part of their
Glioblastomas are tumors with poor prognosis. The treatment of recurrent glioblastoma after a standard first-line treatment is not clearly codified, however, many results in the literature show the benefit of bevacizumab (anti- angiogenic therapy) and it is often proposed in this indication . Tissue
Objectives of the project:
The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
The following primary aims will be addressed:
1. Morphological
1.1 Primary Aim: To describe MRI response rate as regards edema and enhancement of glioblastoma and radiation- related brain enhancement when treated with subcutaneous (SQ) bevacizumab daily. See section 11 for detail on response assessment.
1.2 Secondary Aims: 1.2.1 To characterize toxicities of SQ